Azalea Therapeutics Secures $82 Million in Seed and Series A Financing for In Vivo Genomic Medicine Platform

Wilson Sonsini Goodrich & Rosati has advised Azalea Therapeutics on the transaction. Azalea Therapeutics, a biotechnology company specializing in precision genomic medicines delivered in vivo, has...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here